| Dr Jina Tushar Makadia, MD | |
|
3181 Sam Jackson Park Road, Mail Code L457, Oregon Health & Science University, Div Of Id, Portland, OR 97239-3098 | |
| (503) 494-0591 | |
| Not Available |
| Full Name | Dr Jina Tushar Makadia |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 17 Years |
| Location | 3181 Sam Jackson Park Road, Mail Code L457, Portland, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548558117 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | MD180222 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ohsu Hospital And Clinics | Portland, OR | Hospital |
| Tuality Community Hospital | Hillsboro, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oregon Health And Sciences University/university Medical Group | 4880760107 | 1485 |
| Tuality Medical Group Llc | 7416173414 | 245 |
News Archive
Scientists from EPFL and the University of Wisconsin-Madison have carried out one of the most extensive lipidomics studies to date, connecting almost 150 different lipid species to their respective genetic regulators, revealing signatures of metabolic health and disease.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.
The findings about the brain's awareness of its own body will hopefully lead to better understanding of disorders of self-perception, as for example in brain-damaged patients who no longer recognise their own limbs after stroke, or amputees who still experience pain from limbs that are no longer there.
The University of Rochester Medical Center and Vaccinex, Inc. announced today the award of a key U.S. patent for a technology platform that can assist researchers in finding new treatments for cancer and other diseases. While the technology has many applications, one promising use is for the identification of certain proteins, called monoclonal antibodies, that are capable of seeking out and destroying harmful cells. Several companies have recently developed monoclonal antibodies as treatments for cancer, rheumatoid arthritis, and other conditions. Under an exclusive, worldwide license from the University of Rochester, Vaccinex is using the patented technology to discover and develop new monoclonal antibody therapies.
A major report on lupus from the Secretary of Health and Human Services to the U.S. Congress this week reviews the state of the disease and documents the need for a comprehensive national provider health education program to help eliminate the barriers of racial disparities in the early medical diagnosis and treatment of lupus.
› Verified 3 days ago
| Entity Name | Tuality Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275591984 PECOS PAC ID: 3678486107 Enrollment ID: O20040130000359 |
News Archive
Scientists from EPFL and the University of Wisconsin-Madison have carried out one of the most extensive lipidomics studies to date, connecting almost 150 different lipid species to their respective genetic regulators, revealing signatures of metabolic health and disease.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.
The findings about the brain's awareness of its own body will hopefully lead to better understanding of disorders of self-perception, as for example in brain-damaged patients who no longer recognise their own limbs after stroke, or amputees who still experience pain from limbs that are no longer there.
The University of Rochester Medical Center and Vaccinex, Inc. announced today the award of a key U.S. patent for a technology platform that can assist researchers in finding new treatments for cancer and other diseases. While the technology has many applications, one promising use is for the identification of certain proteins, called monoclonal antibodies, that are capable of seeking out and destroying harmful cells. Several companies have recently developed monoclonal antibodies as treatments for cancer, rheumatoid arthritis, and other conditions. Under an exclusive, worldwide license from the University of Rochester, Vaccinex is using the patented technology to discover and develop new monoclonal antibody therapies.
A major report on lupus from the Secretary of Health and Human Services to the U.S. Congress this week reviews the state of the disease and documents the need for a comprehensive national provider health education program to help eliminate the barriers of racial disparities in the early medical diagnosis and treatment of lupus.
› Verified 3 days ago
| Entity Name | University Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376709535 PECOS PAC ID: 4880760107 Enrollment ID: O20080910000013 |
News Archive
Scientists from EPFL and the University of Wisconsin-Madison have carried out one of the most extensive lipidomics studies to date, connecting almost 150 different lipid species to their respective genetic regulators, revealing signatures of metabolic health and disease.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.
The findings about the brain's awareness of its own body will hopefully lead to better understanding of disorders of self-perception, as for example in brain-damaged patients who no longer recognise their own limbs after stroke, or amputees who still experience pain from limbs that are no longer there.
The University of Rochester Medical Center and Vaccinex, Inc. announced today the award of a key U.S. patent for a technology platform that can assist researchers in finding new treatments for cancer and other diseases. While the technology has many applications, one promising use is for the identification of certain proteins, called monoclonal antibodies, that are capable of seeking out and destroying harmful cells. Several companies have recently developed monoclonal antibodies as treatments for cancer, rheumatoid arthritis, and other conditions. Under an exclusive, worldwide license from the University of Rochester, Vaccinex is using the patented technology to discover and develop new monoclonal antibody therapies.
A major report on lupus from the Secretary of Health and Human Services to the U.S. Congress this week reviews the state of the disease and documents the need for a comprehensive national provider health education program to help eliminate the barriers of racial disparities in the early medical diagnosis and treatment of lupus.
› Verified 3 days ago
| Entity Name | Tuality Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073929782 PECOS PAC ID: 7416173414 Enrollment ID: O20140729000238 |
News Archive
Scientists from EPFL and the University of Wisconsin-Madison have carried out one of the most extensive lipidomics studies to date, connecting almost 150 different lipid species to their respective genetic regulators, revealing signatures of metabolic health and disease.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.
The findings about the brain's awareness of its own body will hopefully lead to better understanding of disorders of self-perception, as for example in brain-damaged patients who no longer recognise their own limbs after stroke, or amputees who still experience pain from limbs that are no longer there.
The University of Rochester Medical Center and Vaccinex, Inc. announced today the award of a key U.S. patent for a technology platform that can assist researchers in finding new treatments for cancer and other diseases. While the technology has many applications, one promising use is for the identification of certain proteins, called monoclonal antibodies, that are capable of seeking out and destroying harmful cells. Several companies have recently developed monoclonal antibodies as treatments for cancer, rheumatoid arthritis, and other conditions. Under an exclusive, worldwide license from the University of Rochester, Vaccinex is using the patented technology to discover and develop new monoclonal antibody therapies.
A major report on lupus from the Secretary of Health and Human Services to the U.S. Congress this week reviews the state of the disease and documents the need for a comprehensive national provider health education program to help eliminate the barriers of racial disparities in the early medical diagnosis and treatment of lupus.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jina Tushar Makadia, MD 8828 Sw Ash Meadows Cir, Apt # 1036, Wilsonville, OR 97070-6224 Ph: (201) 889-7886 | Dr Jina Tushar Makadia, MD 3181 Sam Jackson Park Road, Mail Code L457, Oregon Health & Science University, Div Of Id, Portland, OR 97239-3098 Ph: (503) 494-0591 |
News Archive
Scientists from EPFL and the University of Wisconsin-Madison have carried out one of the most extensive lipidomics studies to date, connecting almost 150 different lipid species to their respective genetic regulators, revealing signatures of metabolic health and disease.
NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.
The findings about the brain's awareness of its own body will hopefully lead to better understanding of disorders of self-perception, as for example in brain-damaged patients who no longer recognise their own limbs after stroke, or amputees who still experience pain from limbs that are no longer there.
The University of Rochester Medical Center and Vaccinex, Inc. announced today the award of a key U.S. patent for a technology platform that can assist researchers in finding new treatments for cancer and other diseases. While the technology has many applications, one promising use is for the identification of certain proteins, called monoclonal antibodies, that are capable of seeking out and destroying harmful cells. Several companies have recently developed monoclonal antibodies as treatments for cancer, rheumatoid arthritis, and other conditions. Under an exclusive, worldwide license from the University of Rochester, Vaccinex is using the patented technology to discover and develop new monoclonal antibody therapies.
A major report on lupus from the Secretary of Health and Human Services to the U.S. Congress this week reviews the state of the disease and documents the need for a comprehensive national provider health education program to help eliminate the barriers of racial disparities in the early medical diagnosis and treatment of lupus.
› Verified 3 days ago
Salona Shrestha, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4805 Ne Glisan St, Portland, OR 97213 Phone: 503-215-2392 | |
Dr. Emmanuel Trungtoan Tavan, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2800 N Vancouver Ave, Suite 230, Portland, OR 97227 Phone: 503-413-2901 | |
Ginevra Lois Liptan, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 6400 Sw Canyon Ct, Ste 100, Portland, OR 97221 Phone: 503-477-9616 Fax: 503-477-9808 | |
Donald Richard Sullivan, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Uhn67, Portland, OR 97239 Phone: 503-494-6949 | |
Dr. Victor Nguyen Pham, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 9205 Sw Barnes Rd, Portland, OR 97225 Phone: 503-216-2906 | |
Richa Uppal, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Sw 13th Ave, Portland, OR 97205 Phone: 503-221-0161 Fax: 503-274-1697 | |
Reem Hasan, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Ppv 350, Portland, OR 97239 Phone: 503-494-8562 |